GlassScriptPhysician profile
Hyeeun Jeong
NPI 1396231999
$6,427.08
in general payments reported to CMS, 2019-2025
26 companies · $3,910 in 2025
The $3,910 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.03 · 2022: $140 · 2023: $479 · 2024: $1,879 · 2025: $3,910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,146 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,145.97 |
| Education | $121.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $973.31 | 2024-2025 | Opzelura, Opzelura |
| Genzyme Corporation | $566.19 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $493.62 | 2024-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $478.54 | 2024-2025 | |
| Leo Pharma INC. | $434.38 | 2024-2025 | Adbry, Anzupgo |
| Abbvie INC. | $433.35 | 2024-2025 | |
| Janssen Biotech, INC. | $369.26 | 2024-2025 | Tremfya |
| Microvention, INC. | $321.99 | 2022-2024 | Stent, Web Aneurysm Embolization System, Lvis Junior |
| Regeneron Healthcare Solutions, INC. | $236.90 | 2024-2025 | Dupixent |
| Stryker Corporation | $231.40 | 2021-2025 | Target, Surpass Evolve |
| Botanix Sb INC | $228.84 | 2025 | Sofdra |
| Ucb, INC. | $227.01 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $214.28 | 2025 | Ebglyss, Taltz |
| Galderma Laboratories, L.P. | $208.82 | 2025 | Nemluvio |
| Pfizer INC. | $179.05 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $163.87 | 2024-2025 | Cabtreo, Siliq |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2022 | |
| Organon LLC | $121.31 | 2025 | |
| Merck Sharp & Dohme LLC | $116.73 | 2023 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $74.42 | 2024-2025 | Sotyktu |
| Depuy Synthes Sales INC. | $51.86 | 2023-2024 | Trufill |
| Medtronic, INC. | $48.88 | 2023 | Kyphon Express II Kyphopak Tray |
| Sanofi US Services INC. | $37.99 | 2025 | |
| Dermavant Sciences, INC. | $36.83 | 2024 | Vtama |
| Mml US, INC. | $31.89 | 2025 | Reactiv8 |
| Lnhc, INC | $21.36 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hyeeun Jeong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.